10/10
09:36 am
xene
Xenon Pharmaceuticals Inc. (NASDAQ: XENE) had its "outperform" rating re-affirmed by analysts at Raymond James. They now have a $50.00 price target on the stock.
Low
Report
Xenon Pharmaceuticals Inc. (NASDAQ: XENE) had its "outperform" rating re-affirmed by analysts at Raymond James. They now have a $50.00 price target on the stock.
10/10
09:36 am
xene
Xenon Pharmaceuticals Inc. (NASDAQ: XENE) had its "outperform" rating re-affirmed by analysts at Raymond James. They now have a $50.00 price target on the stock.
Low
Report
Xenon Pharmaceuticals Inc. (NASDAQ: XENE) had its "outperform" rating re-affirmed by analysts at Raymond James. They now have a $50.00 price target on the stock.
10/10
08:54 am
xene
Rating for XENE
Low
Report
Rating for XENE
10/10
08:54 am
xene
Rating for XENE
Low
Report
Rating for XENE
10/1
07:57 am
xene
Xenon Pharmaceuticals Inc. (NASDAQ: XENE) is now covered by analysts at HC Wainwright. They set a "buy" rating and a $53.00 price target on the stock.
Low
Report
Xenon Pharmaceuticals Inc. (NASDAQ: XENE) is now covered by analysts at HC Wainwright. They set a "buy" rating and a $53.00 price target on the stock.
9/6
07:02 am
xene
Xenon Pharmaceuticals Inc. (NASDAQ: XENE) was upgraded by analysts at William Blair to a "strong-buy" rating.
Medium
Report
Xenon Pharmaceuticals Inc. (NASDAQ: XENE) was upgraded by analysts at William Blair to a "strong-buy" rating.
9/6
07:02 am
xene
Xenon Pharmaceuticals Inc. (NASDAQ: XENE) was upgraded by analysts at William Blair to a "strong-buy" rating.
Medium
Report
Xenon Pharmaceuticals Inc. (NASDAQ: XENE) was upgraded by analysts at William Blair to a "strong-buy" rating.
9/3
10:12 am
xene
Xenon Pharmaceuticals Inc. (NASDAQ: XENE) had its "outperform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $55.00 price target on the stock.
Low
Report
Xenon Pharmaceuticals Inc. (NASDAQ: XENE) had its "outperform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $55.00 price target on the stock.
9/3
10:12 am
xene
Xenon Pharmaceuticals Inc. (NASDAQ: XENE) had its "outperform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $55.00 price target on the stock.
Low
Report
Xenon Pharmaceuticals Inc. (NASDAQ: XENE) had its "outperform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $55.00 price target on the stock.
9/3
09:47 am
xene
Rating for XENE
Low
Report
Rating for XENE
9/3
09:47 am
xene
Rating for XENE
Low
Report
Rating for XENE
8/12
05:39 am
xene
Rating for XENE
Low
Report
Rating for XENE
8/12
05:39 am
xene
Rating for XENE
Low
Report
Rating for XENE
8/9
11:17 am
xene
Xenon Pharmaceuticals Inc. (NASDAQ: XENE) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $65.00 price target on the stock.
Medium
Report
Xenon Pharmaceuticals Inc. (NASDAQ: XENE) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $65.00 price target on the stock.
8/9
11:11 am
xene
Rating for XENE
Medium
Report
Rating for XENE
8/9
09:32 am
xene
Rating for XENE
Medium
Report
Rating for XENE
8/9
09:32 am
xene
Rating for XENE
Medium
Report
Rating for XENE